Molecular Partners (MOLN) vs Tenaya Therapeutics (TNYA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Molecular Partners (MOLN) has outperformed Tenaya Therapeutics (TNYA) over the past year, losing 2.1% versus a loss of 70.3%. Over five years, MOLN leads with a -80.8% price change compared with -97.4% for TNYA. Molecular Partners is the larger company by market cap ($145.9 million vs $122.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MOLN | TNYA |
|---|---|---|
| Share price | $3.81 | $0.5442 |
| Market cap | $145.94M | $122.03M |
| 1-day change | 0.00% | +2.02% |
| YTD return | -12.59% | -23.57% |
| 1-year return | -2.06% | -70.26% |
| 5-year return | -80.76% | -97.35% |
| EPS (TTM) | $-1.71 | $-0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.36 | $2.35 |
| 52-week low | $3.53 | $0.5211 |
| Distance from 52-week high | -28.92% | -76.84% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +172.18% | +488.02% |
| Average volume | 1.15K | 2.26M |
| Shares outstanding | 38.31M | 224.23M |
| Employees | 134 | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MOLN has outperformed TNYA by 68.2 percentage points over the past year.
About Molecular Partners
MOLN stock →Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 134 employees
About Tenaya Therapeutics
TNYA stock →Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 70 employees
MOLN vs TNYA FAQ
Which is bigger, Molecular Partners or Tenaya Therapeutics?
Molecular Partners (MOLN) is larger, with a market capitalization of $145.94M compared with $122.03M for Tenaya Therapeutics (TNYA).
Which stock has performed better over the past year, MOLN or TNYA?
MOLN returned -2.06% over the past 12 months, compared with -70.26% for TNYA (price return, excluding dividends). Past performance does not predict future results.
Are Molecular Partners and Tenaya Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.